Asthma Clinical Trial
Official title:
An Evaluation of Changes in Physician Performance Through Continuous Professional Development
The purpose of this study is to determine whether having physicians evaluate their management of certain diseases as part of board recertification results in improved patient care.
In the year 2000, the American Board of Internal Medicine introduced continuous professional
development as part of its board recertification process. The purpose of these changes were
to achieve the following goals:
- To improve the quality of patient care;
- To affirm the high standards expected of a self-regulating, accountable profession;
- To foster continuing scholarship and self-improvement;
- To offer diplomats a portfolio of credentials attesting to competence; and
- To add value to the health care system.
The most notable change in the new recertification process was the addition of practice
improvement modules (PIMs). These modules require physicians to review how well they manage
a particular chronic disease within their practice and to develop an improvement plan for
their practice. In April 2005, it became a requirement that all internists complete a PIM as
part of board recertification.
Currently, it not known whether having physicians evaluate their management of certain
diseases as part of board recertification will achieve its intended goal of improving
patient care. Therefore, the purpose of this trial is to assess whether practice improvement
modules result in improved clinical performance.
The PIM selected for this study will focus on asthma. As PIMs seek to improve the quality of
care within a practice, the unit of randomization in this study will be clinics (i.e.,
practices) within the Henry Ford Health System. We will enroll practicing, board-certified
internists within the Henry Ford Medical Group (~40 internists or 20 per arm). Clinics (~16
or 8 per arm) will then be randomized to either complete the PIM or not complete the PIM.
Participating internists at a site randomized to complete the PIM will be encouraged to work
together to complete the asthma PIM. Participating internists at control sites will continue
usual care and will not be asked to complete an asthma PIM.
Comparisons: We will assess differences in asthma care by prospectively surveying patients
seen by physicians in the intervention group and control group following the intervention
period. These analyses will be adjusted by the baseline characteristics of asthma patients
seen by participating physicians.
;
Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Single Blind
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04624425 -
Additional Effects of Segmental Breathing In Asthma
|
N/A | |
Terminated |
NCT04410523 -
Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma
|
Phase 2 | |
Active, not recruiting |
NCT03927820 -
A Pharmacist-Led Intervention to Increase Inhaler Access and Reduce Hospital Readmissions (PILLAR)
|
N/A | |
Completed |
NCT04617015 -
Defining and Treating Depression-related Asthma
|
Early Phase 1 | |
Recruiting |
NCT03694158 -
Investigating Dupilumab's Effect in Asthma by Genotype
|
Phase 4 | |
Terminated |
NCT04946318 -
Study of Safety of CSJ117 in Participants With Moderate to Severe Uncontrolled Asthma
|
Phase 2 | |
Completed |
NCT04450108 -
Vivatmo Pro™ for Fractional Exhaled Nitric Oxide (FeNO) Monitoring in U.S. Asthmatic Patients
|
N/A | |
Completed |
NCT03086460 -
A Dose Ranging Study With CHF 1531 in Subjects With Asthma (FLASH)
|
Phase 2 | |
Completed |
NCT01160224 -
Oral GW766944 (Oral CCR3 Antagonist)
|
Phase 2 | |
Completed |
NCT03186209 -
Efficacy and Safety Study of Benralizumab in Patients With Uncontrolled Asthma on Medium to High Dose Inhaled Corticosteroid Plus LABA (MIRACLE)
|
Phase 3 | |
Completed |
NCT02502734 -
Effect of Inhaled Fluticasone Furoate on Short-term Growth in Paediatric Subjects With Asthma
|
Phase 3 | |
Completed |
NCT01715844 -
L-Citrulline Supplementation Pilot Study for Overweight Late Onset Asthmatics
|
Phase 1 | |
Terminated |
NCT04993443 -
First-In-Human Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of LQ036
|
Phase 1 | |
Completed |
NCT02787863 -
Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology
|
Phase 4 | |
Recruiting |
NCT06033833 -
Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study
|
Phase 2 | |
Completed |
NCT03257995 -
Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts in Adult Subjects With Asthma.
|
Phase 2 | |
Completed |
NCT02212483 -
Clinical Effectiveness and Economical Impact of Medical Indoor Environment Counselors Visiting Homes of Asthma Patients
|
N/A | |
Recruiting |
NCT04872309 -
MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology
|
||
Withdrawn |
NCT01468805 -
Childhood Asthma Reduction Study
|
N/A | |
Recruiting |
NCT05145894 -
Differentiation of Asthma/COPD Exacerbation and Stable State Using Automated Lung Sound Analysis With LungPass Device
|